Search results
Results from the WOW.Com Content Network
Memantine/donepezil, sold under the brand name Namzaric among others, is a fixed dose combination medication used for the treatment of dementia of the Alzheimer's type. [1] It contains memantine , as the hydrochloride, a NMDA receptor antagonist ; and donepezil as the hydrochloride, an acetylcholinesterase inhibitor . [ 1 ]
Donepezil, sold under the brand name Aricept among others, is a medication used to treat dementia of the Alzheimer's type. [ 3 ] [ 4 ] [ 8 ] It appears to result in a small benefit in mental function and ability to function. [ 9 ]
[1] [2] [3] ChEIs may be used as drugs for Alzheimer's and myasthenia gravis , and also as chemical weapons and insecticides . [ 4 ] [ 5 ] Side effects when used as drugs may include loss of appetite , nausea , vomiting , loose stools , vivid dreams at night, dehydration , rash , bradycardia , peptic ulcer disease , seizures , weight loss ...
Not only that, they had a 52 percent lower risk of vascular dementia, and a 39 percent lower risk of Alzheimer’s dementia. People who took SGLT-2 inhibitors for longer periods of time seemed to ...
A follow-up period of at least 10-15 years would be ideal to better evaluate long-term associations between antibiotic use and cognitive decline, as dementia and cognitive impairments often ...
[1] [2] Agents or methods of neuroenhancement are intended to affect cognitive, social, psychological, mood, or motor benefits beyond normal functioning. Pharmacological neuroenhancement agents may include compounds thought to be nootropics , such as modafinil , [ 1 ] [ 3 ] caffeine , [ 4 ] [ 5 ] and other drugs used for treating people with ...
It also can help improve the individual’s relationship with the person leading this kind of therapy, often their caregiver. In that way, the Chevy commercial offers an accurate depiction of how ...
Its efficacy is similar to donepezil and tacrine. Doses below 6 mg/d may be ineffective. The effects of this kind of drug in different kinds of dementia (including Alzheimer's dementia) are modest, and it is still unclear which AChE (BChE) esterase inhibitor is better in Parkinson's dementia, though rivastigmine is well-studied.